Voyager Therapeutics Announces Selection of Gene Therapy Development Candidate for Friedreich’s Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment

February 26, 2024

https://www.globenewswire.com/news-release/2024/02/26/2834995/36461/en/Voyager-Therapeutics-Announces-Selection-of-Gene-Therapy-Development-Candidate-for-Friedreich-s-Ataxia-in-Collaboration-with-Neurocrine-Biosciences-Triggering-Milestone-Payment.html

LEXINGTON, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the joint steering committee with its collaborator Neurocrine Biosciences has selected a lead development candidate in the Friedreich’s ataxia (FA) program. The candidate combines a frataxin (FXN) gene replacement payload with an intravenously administered, blood-brain barrier penetrant, novel capsid derived from Voyager’s TRACER™ capsid discovery platform. The companies expect the program to advance into first-in-human clinical trials in 2025.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.